83 related articles for article (PubMed ID: 742112)
1. [Exertion insufficiency during beta blocker therapy in the hyperkinetic heart syndrome].
Niehues B; Hermanns L; Kortenbruck R; Behrenbeck DW; Hilger HH
Verh Dtsch Ges Inn Med; 1978; (84):736-9. PubMed ID: 742112
[No Abstract] [Full Text] [Related]
2. Mepindolol sulfate in the hyperkinetic heart syndrome.
Bonelli J
Int J Clin Pharmacol Ther Toxicol; 1984 Jan; 22(1):42-4. PubMed ID: 6698659
[TBL] [Abstract][Full Text] [Related]
3. Further indications for Visken.
Holmes D; Schutz W
Indian Heart J; 1972 Jun; 24():Suppl 1:244-8. PubMed ID: 4667018
[No Abstract] [Full Text] [Related]
4. Treatment of psycho-neurotic conversion reactions with pindolol. (Effect on cardio-vascular response to exercise).
Kelesidis G; Hagis P; Samaras C
Indian Heart J; 1972 Jun; 24():Suppl 1:238-43. PubMed ID: 4147280
[No Abstract] [Full Text] [Related]
5. The effects of propranolol in essential circulatory hyperkinesis.
Török E; Matos L; Rausch J; Simonyi J
Int Z Klin Pharmakol Ther Toxikol; 1969 Jul; 2(3):246-52. PubMed ID: 4902019
[No Abstract] [Full Text] [Related]
6. Elevated plasma catecholamines in young hypertensive and hyperkinetic patients: effect of pindolol.
Dominiak P; Grobecker H
Br J Clin Pharmacol; 1982; 13(Suppl 2):381S-390S. PubMed ID: 7104155
[No Abstract] [Full Text] [Related]
7. [Effect of a beta receptor blocker on cardiac output--studies in essential hypertension and hyperkinetic heart syndrome with reference to plasma adrenaline and noradrenaline levels].
Walter I; Kusus T; Wagner K; Lydtin H
Verh Dtsch Ges Inn Med; 1973; 79():1010-3. PubMed ID: 4790081
[No Abstract] [Full Text] [Related]
8. [Beta receptor blocking agents in hypercirculatory syndromes and in high performance athletes].
Gattenlöhner W; Schneider KW; Rost R
Med Welt; 1969 Oct; 42():2298-306. PubMed ID: 4901510
[No Abstract] [Full Text] [Related]
9. [Hyperkinetic heart syndrome].
Lohmöller G; Lydtin H
Fortschr Med; 1971 Aug; 89(22):864-7. PubMed ID: 4403734
[No Abstract] [Full Text] [Related]
10. [Study of the action of pindolol during rest and exertion on a group of subjects with hypertension].
Debru JL; Mikler F; Grubier M; Cau G; Muller JM; Mallion JM
Ann Cardiol Angeiol (Paris); 1976 Oct; 25(5):393-7. PubMed ID: 984726
[No Abstract] [Full Text] [Related]
11. [Idiopathic cardiac hyperkinetic syndrome. Critical study].
Tourniaire A; Blum J; Tartulier M; Deyrieux F; Madignier M
Arch Mal Coeur Vaiss; 1970 Apr; 63(4):539-63. PubMed ID: 4989083
[No Abstract] [Full Text] [Related]
12. [The effect of beta-receptor-blocking agents on the ergometric performance study in hypertensive regulation disorders and hyperkinetic heart syndrome].
Enenkel W; Polzer K; Kubicek F
Wien Med Wochenschr; 1968 Oct; 118(42):874-6. PubMed ID: 5708730
[No Abstract] [Full Text] [Related]
13. [Hyperkinetic heart syndrome].
Medved R; Pavisic-Medved V
Lijec Vjesn; 1970; 92(4):451-60. PubMed ID: 5208220
[No Abstract] [Full Text] [Related]
14. Clinical-pharmacological evaluation of a new beta blocker, GYKI-41099 (tobanum).
Török E; Istvánffy M; Halmágyi M; Wagner M; Csukás M
Int J Clin Pharmacol Ther Toxicol; 1980; 18(5):200-7. PubMed ID: 6104634
[TBL] [Abstract][Full Text] [Related]
15. [Hemodynamic evaluation of pindolol].
Biffani G; Santini M
Minerva Cardioangiol; 1976 Sep; 24(9):613-8. PubMed ID: 1012501
[No Abstract] [Full Text] [Related]
16. Comparative clinical and hemodynamic investigations on two beta-receptor blocking agents (pindolol and mepindolol) in normal subjects.
Wink K
Int J Clin Pharmacol Ther Toxicol; 1984 Mar; 22(3):126-30. PubMed ID: 6715080
[TBL] [Abstract][Full Text] [Related]
17. [Hyperkinetic heart syndrome].
Linss G
Z Arztl Fortbild (Jena); 1985; 79(2):63-5. PubMed ID: 2859706
[No Abstract] [Full Text] [Related]
18. Human cardiovascular effects of alprenolol, a beta-adrenergic blocker: hemodynamic, antiarrhythmic, and antianginal.
Wasserman AJ; Proctor JD; Allen FJ; Kemp VE
J Clin Pharmacol J New Drugs; 1970; 10(1):37-49. PubMed ID: 4391785
[No Abstract] [Full Text] [Related]
19. [Juvenile hypertension and idiopathic hyperkinetic heart syndrome].
Hayashi T; Yagi S
Nihon Rinsho; 1984 Feb; 42(2):455-9. PubMed ID: 6716700
[No Abstract] [Full Text] [Related]
20. [Clinical test of a new beta-receptor blockader in labile hypertension].
Walter I; Kusus T; Lydtin H
Verh Dtsch Ges Inn Med; 1971; 77():940-3. PubMed ID: 5156091
[No Abstract] [Full Text] [Related]
[Next] [New Search]
